Mixing Studies and Correction Test in Coagulation

12 Questions

What is the aim of the mixing study in checking abnormal clotting time result?

To differentiate clotting time prolongation due to a coagulation factor deficiency or an inhibitor

What is the basic principle behind the mixing study?

To correct for a factor deficiency using normal plasma

When does the mixing study take place?

Immediately after PT or aPTT measured or incubated

What does a corrected clotting time after mixing suggest?

Presence of a coagulation factor deficiency

What is the significance of confirming probable coagulation deficiencies?

It aids in selecting the factor assay

What does a clotting time that does not correct after mixing suggest?

Presence of a specific inhibitor

In which pathway does the activation of factor 7 occur?

Extrinsic pathway

Which factor is responsible for the activation of factor 10 in the extrinsic pathway?

Factor 7

Where does the intrinsic pathway begin?

Inside the blood vessel

What role does factor 13 play in the clotting process?

Stabilizes fibrin

Which pathway ultimately leads to the formation of a fibrin network that covers the surface of the platelet plug?

Common pathway

What is the initial source of tissue factor in the extrinsic pathway?

Damage to tissue outside the blood vessel

Study Notes

Mixing Study

The aim of the mixing study is to check abnormal clotting time results by mixing the patient's plasma with normal plasma.
The basic principle behind the mixing study is to identify whether the abnormal clotting time is due to a factor deficiency or an inhibitor.

Clotting Pathways

The mixing study takes place when a patient's clotting time is abnormal to determine the cause of the abnormality.
A corrected clotting time after mixing suggests that the abnormality is due to a factor deficiency.
Confirming probable coagulation deficiencies is significant because it helps identify the underlying cause of bleeding disorders.

Coagulation Factors

A clotting time that does not correct after mixing suggests the presence of an inhibitor.
Factor 7 is activated in the extrinsic pathway.
Factor 7 is responsible for the activation of factor 10 in the extrinsic pathway.
The intrinsic pathway begins with the activation of factor 12 (Hageman factor).
Factor 13 (fibrin-stabilizing factor) plays a role in the clotting process by cross-linking fibrin strands to form a stable clot.
The extrinsic pathway ultimately leads to the formation of a fibrin network that covers the surface of the platelet plug.
The initial source of tissue factor in the extrinsic pathway is damaged tissue cells or cells in the blood vessel wall.